Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer​

August 19, 2025 Imbria Pharmaceuticals Appoints Physician-Scientist Albert M. Kim, MD, PhD, as Chief Medical Officer BOSTON, Mass., August 19, 2025 – Imbria Pharmaceuticals, Inc., (“Imbria”), a clinical-stage company revolutionizing cardiovascular disease treatment by targeting cardiac energy metabolism, today announced the appointment of physician-scientist, Albert M. Kim, MD, PhD, FACC, FHRS, as Chief Medical Officer […] The post Imbria Pharmaceuticals Appoints Physician-Scientist Albert M.